Allogeneic bone marrow transplantation for adult acute lymphoblastic leukemia: a single-centre experience
Autor: | S. K. Ma, YL Kwong, Li Chong Chan, TK Chan, Raymond Liang, Wing-Yan Au, Akw Lie, Edmond Chiu, Chor Sang Chim, Charles Kai-Wu Lee |
---|---|
Rok vydání: | 1998 |
Předmět: |
Cancer Research
medicine.medical_specialty Chemotherapy business.industry Marrow transplantation medicine.medical_treatment Hematology General Medicine medicine.disease Gastroenterology Surgery Leukemia medicine.anatomical_structure Oncology Internal medicine Acute lymphocytic leukemia medicine Adult Acute Lymphoblastic Leukemia Methotrexate Bone marrow Autogenous bone business medicine.drug |
Zdroj: | Hematological Oncology. 16:163-168 |
ISSN: | 1099-1069 0278-0232 |
Popis: | Between 1990 and 1997, we performed 29 allogeneic BMTs for acute lymphoblastic leukemia (ALL) patients with HLA-identical sibs. Their median age was 31 years (range 15 to 43); there were 15 males and 14 females. The conditioning protocol was Cy-TBI (n = 15), VP16-Cy-TBI(n = 12), CBV (n = 1) and Bu-Cy (n = 1). Cyclosporin and methotrexate were used for GVHD prophylaxis. The median disease-free survival (DFS) was 12 months (range 1 to 92) with an actuarial 4-years DFS of 42.3 per cent. Three patients died of transplant-related complications before 100 days. Relapse occurred in 11 cases at a median time of 5 months (range 3 to 14). All nine patients relapsing within one year died form resistant leukemia. Three patients died of late treatment-related complications. There were 13 survivors (median follow-up 38 months, range 12-98), with 12 in remission. Only four had limited cGVHD, and all had 100 per cent performance scores. One patient also cleared her chronic hepatitis B carrier status due to acquired immunity. The DFS rates amongst CR1 cases and R1/CR2 cases were comparable (p = 0.39). No long-term DFS is obtained from patients with resistant disease (n = 4). The survival results for BMT at CR1 were superior to those using intensive chemotherapy consolidation (p = 0.29), mainly due to poor late results in the chemotherapy arm. For young ALL patients with HLA-matched siblings, the option of BMT should be considered in light of local consolidation survival results. |
Databáze: | OpenAIRE |
Externí odkaz: |